BeOne Medicines (ONC) Director Wang Xiaodong Sells $11M of Stock

On October 13, 2026, Wang Xiaodong, a Director at BeOne Medicines AG (ONC), sold 31,027 shares for approximately $10,890,073.65 at a price of $350.99 each. This planned sale reflects ongoing insider activity at the company.

Inside Wang Xiaodong's Trade

Wang Xiaodong's transaction comes as part of a planned sale, and it represents a significant move for him given the value of the shares sold. The sale did not change his overall stake, but it highlights his activity during a period of stock performance above key moving averages.

Other Institutional Activity in BeOne Medicines AG

Several other institutional investors have also been active in BeOne Medicines. Baker Bros. Advisors, LP holds 8,801,567 shares worth about $3.25 billion, while Primecap Management Company increased its stake by 32,836 shares, totaling 5,007,931 shares valued at about $1.85 billion. Capital International Investors added 51,567 shares, bringing its total to 4,210,221 shares worth about $1.55 billion. In contrast, FMR, LLC reduced its holdings by 1,215,254 shares, ending with 2,478,527 shares valued at about $914.7 million.

BeOne Medicines AG Stock Down 1.6%

As of October 16, 2026, BeOne Medicines' stock was recently traded around $367.93, which is above its 50-day moving average by 2.4% and its 200-day moving average by 14.2%. However, it is still below its 52-week high of $385.22 by 4.5%. The stock's price is also below the analysts' average target price of $436.46 by about 15.7%.

Recent Earnings

BeOne Medicines reported trailing twelve-month revenue of $6.13 billion with an earnings per share (EPS) of $5.59. The company has shown a year-over-year revenue growth of 29.6% and a net margin of 10.7%. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at BeOne Medicines AG

Before Wang Xiaodong's sale, several insiders were active in buying shares. On June 11, 2026, Sawyers Charles Lazelle purchased 18,980 shares, and Lee Chan Henry bought 45,071 shares. Xiaodong Wang himself bought 193,492 shares on the same day. Earlier, on June 23, 2026, Lai Wang, President of Global R&D, sold 1,068 shares at an average price of $276.74.

Analysts Set New Price Targets

Analysts have maintained a positive outlook for BeOne Medicines AG. On October 1, 2026, JP Morgan maintained an Overweight rating with a target price of $445. On October 7, 2026, Truist Securities also maintained a Buy rating with a target of $420. The consensus recommendation remains a strong buy, with a mean price target of $436.46 based on 27 analyst opinions.

About BeOne Medicines AG

BeOne Medicines AG is an oncology company based in Basel, Switzerland. It focuses on discovering and developing treatments for cancer patients across the United States, China, Europe, and beyond. The company's strong revenue growth reflects its commitment to advancing cancer therapies.

Bottom Line

Investors will be watching BeOne Medicines closely ahead of its next earnings report on November 5, 2026. Wang Xiaodong's significant sale adds to the ongoing narrative of insider activity at the company, which is supported by a generally positive outlook from analysts.